Speaker Profile
Keiji Furuuchi

Keiji Furuuchi PhD

Oncology, Immunology and Microbiology
Woodcliff Lake, New Jersey, United States of America

Connect with the speaker?

Keiji Furuuchi, PhD is currently leading Preclinical development as a director, EPAT (Epochal Precision Anti-Cancer Therapeutics), Eisai, Inc, since the merger of immunotherapy development and pharmacology development in April 2018. Prior to the position, he was an assistant professor at Thomas Jefferson University and he joined antibody development in the Morphotek since 2009. Currently, his department conducts various preclinical evaluations for various projects in EPAT.
EVENTS & ACTIVITIES (Speaking, Spoken, and Authored)